NecroX-5 - Calcium Channel 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENecroX-5Cat. No.: HY-104015CAS No.: 1383718-29-3分式: CHNOS分量: 645.81作靶點: Calcium Channel作通路: Membrane Transporter/Ion Channel; Neuronal Signaling儲存式: 4C, stored under nitrogen* In solvent : -80C, 6 months; -20C, 1 month (stored u

2、ndernitrogen)溶解性數(shù)據(jù)體外實驗 DMSO : 170 mg/mL (263.24 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.5484 mL 7.7422 mL 15.4844 mL5 mM 0.3097 mL 1.5484 mL 3.0969 mL10 mM 0.1548 mL 0.7742 mL 1.5484 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的?/p>

3、備液，再依次添加助溶劑(為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.83 mg/mL (4.38 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.83 mg/mL (4.38 mM); Clear solutionBIOLOGICA

4、L ACTIVITY1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 NecroX-5NecroX 的衍物，降低細胞內(nèi)鈣離 (calcium) 濃度，具有抗炎、抗癌的作。IC50 & Target Calcium channel 1體外研究 NecroX-5 (10 or 40 M) inhibits breast cancer cell migration, which is correlated with mitoROS reduction, andmediated by AKT inhibition. NecroX-5 (10 M)

5、 decreases intracellular calcium concentration in 4T1 cells byblocking Ca2+ influx, which mediated the inhibition of cell migration, AKT downregulation and the reduction ofmitochondrial ROS levels 1. NecroX-5 (10 M) treatment for 24 h, effectively decreases the increased TNF,TGF1, pSmad2 and the exp

6、ression of Dcn in LPS-stimulated H9C2 cells 2.體內(nèi)研究 NecroX-5 (2.5 mg/kg, everyday other day) inhibits breast cancer cell metastasis in TUBO-P2J tumour-bearingmice 1.REFERENCES1. Park JH, et al. NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels. Int

7、 J Oncol. 2017Jan;50(1):185-192.2. Thu VT, et al. NecroX-5 exerts anti-inflammatory and anti-fibrotic effects via modulation of the TNF/Dcn/TGF1/Smad2 pathway inhypoxia/reoxygenation-treated rat hearts. Korean J Physiol Pharmacol. 2016 May;20(3):305-14.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use